Can liver or hepatobiliary stress impair T4-to-T3 conversion?

The liver has a substantial direct role in thyroid-hormone metabolism, and clinically important liver dysfunction can reduce conversion of inactive thyroxine (T4) to active triiodothyronine (T3). This is most clearly established in cirrhosis and severe systemic illness rather than in uncomplicated biliary disease.

Clinical evidence

• Peripheral deiodination supplies approximately 80% of circulating T3. Hepatic production is estimated at roughly 8–15 nmol/day, or 20–35% of extrathyroidal T3 production—substantial enough for the liver to be considered a major conversion site, though not necessarily the dominant source in euthyroid people.
• In a human isotope study, T4-to-T3 conversion averaged 15.6% in cirrhosis versus 35.7% in controls (P<0.001). Lower T3 correlated with higher bilirubin and lower albumin, linking impaired activation to severity of liver dysfunction.
• Liver disease commonly produces a low-T3, higher-reverse-T3 pattern, often without an elevated TSH. This pattern reflects altered hormone activation and clearance during illness, not automatically primary hypothyroidism.

Mechanistic explanation

• Hepatocytes express type 1 deiodinase (DIO1), which performs outer-ring 5′-deiodination of T4 to bioactive T3.
• Hepatic stress is associated with lower DIO1 activity; in critical illness, liver D1 activity was inversely related to bilirubin. Hepatocyte experiments also found approximately 42% inhibition of T4 uptake/deiodination with patient serum, correlating with bilirubin and albumin-related measures.

Clinical implications

• Acute illness, inflammation, nutrition, medications, renal function, and altered binding proteins can compound these changes. Evidence is less specific for mechanical biliary obstruction or proof of reversal after decompression.
• Bottom line: Significant liver dysfunction can meaningfully impair peripheral T4-to-T3 activation. Low T3 during hepatobiliary illness should be interpreted with TSH, free T4, bilirubin, albumin, clinical severity, and repeat testing during recovery—not as a stand-alone indication for thyroid-hormone treatment.